

**Related Party Disclosures**

**i. Parties where control exists:**

- a) Sanofi S.A. France, ultimate holding Company
- b) Hoechst GmbH, Germany, holding Company

**ii. Other related parties in Sanofi Group where common control exists and with whom transactions have taken place during the reporting year.**

Sanofi-Aventis Singapore Pte. Limited  
Francopia S.A.R.L.  
Sanofi-Aventis Deutschland GmbH  
Sanofi-Aventis Groupe S.A.  
Sanofi Lanka Limited  
Sanofi Chimie S.A. \*  
Sanofi-aventis Philippines Inc. \*  
Sanofi Healthcare India Private Limited  
Sanofi Winthrop Industrie S.A.  
Sanofi-Aventis Pakistan Limited \*  
Sanofi Aventis Arabia Co. Ltd. \*  
Sanofi India Limited Provident Fund  
Sanofi US Services Inc. \*  
Aventis Pharma UK Investments Ltd. \*

Sanofi Vietnam Shareholding Company  
SANOFI-AVENTIS GESTION SA \*  
Sanofi-aventis Healthcare Pty Ltd \*  
\* No transactions during the year

**iii. Key management personnel of the Company for the year**

Mr. Rajaram Narayanan - Managing Director (till the closure of business of April 10, 2022)  
Mr. Cherian Mathew - Whole Time Director  
Mr. Vaibhav Karandikar - Chief Financial officer and Whole time director  
Ms. Radhika Shah - Company Secretary  
Mr. Rudolf Hrosz - Managing Director (w.e.f June 01, 2022)

**iv. Non-Executive Directors**

Mr. Marc-Antoine Lucchini  
Mr. Charles Billard

**v. Independent Directors**

Mr. Aditya Narayan  
Mrs. Usha Thorat  
Mr. Rahul Bhatnagar

vi. Transactions during the year		(₹ in Million)
Particulars	June 30, 2022	
<b>Ultimate Holding Company</b>		
Dividend paid		2
Expenses recharged		(20)
<b>Total</b>		<b>(18)</b>
<b>Holding Company</b>		
Dividend paid		6,813
<b>Other related Parties</b>		
<b>Sale of Products and Other Operating Income</b>		
Sanofi-Aventis Singapore Pte. Limited		1,936
Others		102
<b>Total</b>		<b>2,037</b>
<b>Purchase of Raw Materials and Stock- in- trade</b>		
Sanofi-Aventis Singapore Pte. Limited		1,387
Others		*
Sanofi Healthcare India Private Limited		1,979
<b>Total</b>		<b>3,366</b>
<b>Expenses recharged to other companies</b>		
Sanofi-Aventis Groupe S.A.		1
Sanofi Healthcare India Private Limited		6
Others		*
<b>Total</b>		<b>7</b>
<b>Sale of Services</b>		
Sanofi Healthcare India Private Limited		703
Sanofi-Aventis Singapore Pte. Limited		102
Others		16
<b>Total</b>		<b>821</b>
<b>Rent Income</b>		
Sanofi Healthcare India Private Limited		1
<b>Rent Paid</b>		
Sanofi Healthcare India Private Limited		*
<b>Interest income on loans</b>		
Sanofi Healthcare India Private Limited		122
<b>Total</b>		<b>122</b>
<b>Expenses recharged by other companies</b>		
Sanofi Healthcare India Private Limited		17
Sanofi-Aventis Groupe S.A.		23
<b>Total</b>		<b>40</b>
<b>Contribution to In-house Trust for Post Employment Benefits - Provident Fund</b>		
Sanofi India Limited Provident Fund #		176
<b>Payment towards Intangibles under development</b>		
Sanofi Healthcare India Private Limited		1
<b>Total</b>		<b>1</b>

# Including contribution by employees.

\* denotes figure less than a million

(₹ in Million)

Particulars	June 30, 2022
<b>Key Management Personnel Remuneration # #</b>	
<b>Remuneration</b>	
Mr. Rajaram Narayanan	33
Mr. Vaibhav Karandikar	13
Mr. Cherian Mathew	16
Mr. Rudolf Hrosz	2
Ms. Radhika Shah	5
<b>Total</b>	<b>69</b>

<b>Share based benefit</b>	
Mr. Vaibhav Karandikar	2
Mr. Rudolf Hrosz	1
Mr. Cherian Mathew	3
<b>Total</b>	<b>6</b>

# # Excludes Provision for Employee Benefits

Particulars	June 30, 2022
<b>Sitting Fees to Non- Executive Directors</b>	
Mr. Aditya Narayan	1
Ms. Usha Thorat	1
Mr. Rahul Bhatnagar	1
<b>Total</b>	<b>3</b>
<b>Commission to Non - Executive Directors</b>	
Mr. Aditya Narayan	2
Ms. Usha Thorat	1
Mr. Rahul Bhatnagar	1
<b>Total</b>	<b>4</b>

\* denotes figure less than a million

**Terms and conditions of transactions with related parties**

The sales, services and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. For the period ended June 30, 2022, the Company has not recorded any impairment of receivables relating to amounts owed by related parties (December 31, 2021: Nil). This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

**vii. Outstanding as at June 30, 2022**

Particulars	June 30, 2022
<b>Trade Receivables</b>	
Sanofi-Aventis Singapore Pte. Limited	521
Sanofi Healthcare India Private Limited	232
Others	3
<b>Total</b>	<b>756</b>
<b>Trade Payables</b>	
Sanofi-Aventis Singapore Pte. Limited	478
Sanofi Healthcare India Private Limited	542
Others	30
<b>Total</b>	<b>1,050</b>
<b>Other Financial Liabilities</b>	
Sanofi Healthcare India Private Limited	86
<b>Loan receivable</b>	
Sanofi Healthcare India Private Limited (Refer Note 1 below)	4,450

1) Loans given to Sanofi Healthcare India Private Limited at the rate of interest of 5.5% p.a ( 7.5% till April 15, 2021)  
Maximum balance outstanding during the year ₹ 4,450 Million ( December 31, 2021 : ₹ 4,450 Million) from Sanofi Healthcare India Private  
The said loans have been proposed to be utilized by Sanofi Healthcare India Private Limited for business purpose.  
The Loans have been given against corporate guarantee by Sanofi S.A. France. The Maturity date of same is April 15, 2023.

